- Home
- CELC vs AB Comparison
CELC vs AB Comparison
Compare CELC & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELC | AB |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.8B |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CELC | AB |
|---|---|---|
| Price | $114.28 | $38.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $106.63 | $42.00 |
| AVG Volume (30 Days) | ★ 527.9K | 374.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | ★ 8.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.40 |
| P/E Ratio | ★ N/A | $13.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $32.28 |
| 52 Week High | $120.32 | $44.11 |
Technical Indicators
Market Signals| Indicator | CELC | AB |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 43.07 |
| Support Level | $97.75 | N/A |
| Resistance Level | $114.54 | $39.64 |
| Average True Range (ATR) | 5.14 | 1.04 |
| MACD | 0.36 | -0.07 |
| Stochastic Oscillator | 63.53 | 34.47 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of July 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (36% of AUM) and equity (42%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.